Literature DB >> 1689995

Mapping and characterization of neutralizing epitopes of glycoproteins gIII and gp50 of the Indiana-Funkhauser strain of pseudorabies virus.

N E Coe1, W L Mengeling.   

Abstract

Neutralizing monoclonal antibodies directed against pseudorabies glycoproteins gIII or gp50 were produced. Using these antibodies in competitive binding ELISAs, three overlapping epitopes for gp50 and two nonoverlapping epitopes for gIII were mapped.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1689995     DOI： 10.1007/bf01310710

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  8 in total

1.  Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells.

Authors:  C C Marchioli; R J Yancey; E A Petrovskis; J G Timmins; L E Post
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  A vaccine strain of pseudorabies virus with deletions in the thymidine kinase and glycoprotein X genes.

Authors:  C C Marchioli; R J Yancey; R C Wardley; D R Thomsen; L E Post
Journal:  Am J Vet Res       Date:  1987-11       Impact factor: 1.156

3.  Size and antigenic comparisons among the structural proteins of selected autonomous parvoviruses.

Authors:  W L Mengeling; J F Ridpath; A C Vorwald
Journal:  J Gen Virol       Date:  1988-04       Impact factor: 3.891

4.  Analysis of pseudorabies virus glycoprotein gIII localization and modification by using novel infectious viral mutants carrying unique EcoRI sites.

Authors:  J P Ryan; M E Whealy; A K Robbins; L W Enquist
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

5.  Production and characterization of monoclonal antibodies directed against pseudorabies virus.

Authors:  L M Wathen; K B Platt; M W Wathen; R A Van Deusen; C A Whetstone; E C Pirtle
Journal:  Virus Res       Date:  1985-12       Impact factor: 3.303

6.  Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies.

Authors:  N O Lussenhop; R Goertz; M Wabuke-Bunoti; R Gehrz; B Kari
Journal:  Virology       Date:  1988-06       Impact factor: 3.616

7.  Identification of the pseudorabies virus glycoprotein gp50 as a major target of neutralizing antibodies.

Authors:  M Eloit; D Fargeaud; R L'Haridon; B Toma
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

8.  Efficacy of an inactivated virus vaccine for prevention of porcine parvovirus-induced reproductive failure.

Authors:  W L Mengeling; T T Brown; P S Paul; D E Gutekunst
Journal:  Am J Vet Res       Date:  1979-02       Impact factor: 1.156
  8 in total
  5 in total

1.  Pseudorabies virus glycoprotein L is necessary for virus infectivity but dispensable for virion localization of glycoprotein H.

Authors:  B G Klupp; W Fuchs; E Weiland; T C Mettenleiter
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 2.  Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine.

Authors:  Lisa E Pomeranz; Ashley E Reynolds; Christoph J Hengartner
Journal:  Microbiol Mol Biol Rev       Date:  2005-09       Impact factor: 11.056

3.  Pseudorabies virus glycoproteins gII and gp50 are essential for virus penetration.

Authors:  I Rauh; T C Mettenleiter
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

4.  Construction of bovine herpesvirus-1 (BHV-1) recombinants which express pseudorabies virus (PRV) glycoproteins gB, gC, gD, and gE.

Authors:  H Otsuka; X Xuan
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

5.  Induction of protective immunity and neutralizing antibodies to pseudorabies virus by immunization of anti-idiotypic antibodies.

Authors:  T Tsuda; T Onodera; T Sugimura; Y Murakami
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.